{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:59:19Z","timestamp":1792299559329,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jns.2025.123577","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T19:09:58Z","timestamp":1749236998000},"page":"123577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"475","author":[{"given":"Tamar","family":"Kvartskhava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Freudenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Angstwurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Linker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2025.123577_bb0005","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211007687","article-title":"Inflammation in multiple sclerosis","volume":"14","author":"Haase","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"11","key":"10.1016\/j.jns.2025.123577_bb0010","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jns.2025.123577_bb0015","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1212\/WNL.0000000000003078","article-title":"The 11-year long-term follow-up study from the randomized BENEFIT CIS trial","volume":"87","author":"Kappos","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2025.123577_bb0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(09)70237-6","article-title":"Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial","volume":"8","author":"Kappos","year":"2009","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.123577_bb0025","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210142","article-title":"Long-term treatment with Ocrelizumab in patients with early-stage relapsing MS: nine-year data from the OPERA studies open-label extension","volume":"104","author":"Cerqueira","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123577_bb0030","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.jns.2025.123577_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jns.2025.123577_bb0040","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.123577_bb0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jns.2025.123577_bb0050","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2025.123577_bb0055","first-page":"13","article-title":"Using personalized prognosis in the treatment of relapsing multiple sclerosis: a practical guide","author":"van Wijmeersch","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2025.123577_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: an update","volume":"30","author":"D\u00edaz","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.123577_bb0065","author":"FDA approves new drug to treat multiple sclerosis"},{"key":"10.1016\/j.jns.2025.123577_bb0070","series-title":"Ocrevus","author":"European Medicines Agency (EMA)","year":"2025"},{"issue":"4","key":"10.1016\/j.jns.2025.123577_bb0075","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000719","article-title":"Ocrelizumab initiation in patients with MS: a multicenter observational study","volume":"7","author":"Ellwardt","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2025.123577_bb0080","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/1531-8249(200006)47:6<694::AID-ANA2>3.0.CO;2-W","article-title":"The role of B cells and autoantibodies in multiple sclerosis","volume":"47","author":"J","year":"2000","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.123577_bb0085","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00415-022-11350-1","article-title":"Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study","volume":"270","author":"Capasso","year":"2023","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.123577_bb0090","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s13311-022-01252-5","article-title":"Does Ocrelizumab limit multiple sclerosis progression? Current evidence from clinical, MRI, and fluid biomarkers","volume":"19","author":"Margoni","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jns.2025.123577_bb0095","author":"European Medicines Agency (EMA)"},{"issue":"24","key":"10.1016\/j.jns.2025.123577_bb0100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.0000000000009636","article-title":"The 2013 clinical course descriptors for multiple sclerosis: a clarification","volume":"94","author":"Lublin","year":"2020","journal-title":"Neurology"},{"issue":"4 Suppl 2","key":"10.1016\/j.jns.2025.123577_bb0105","doi-asserted-by":"crossref","first-page":"S831","DOI":"10.1007\/s100720070021","article-title":"A prospective study on the prognosis of multiple sclerosis","volume":"21","author":"Amato","year":"2000","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2025.123577_bb0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s42466-019-0005-5","article-title":"Navigating choice in multiple sclerosis management","volume":"1","author":"Linker","year":"2019","journal-title":"Neurol. Res. Pract."},{"key":"10.1016\/j.jns.2025.123577_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935019","article-title":"Expert opinion on the use of cladribine tablets in clinical practice","volume":"13","author":"S\u00f8rensen","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.jns.2025.123577_bb0120","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.jns.2025.123577_bb0125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(11)70020-5","article-title":"Alemtuzumab versus interferon \u03b2-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes","volume":"10","author":"Coles","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2025.123577_bb0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"J. Neurol."},{"issue":"13","key":"10.1016\/j.jns.2025.123577_bb0135","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1177\/1352458514532317","volume":"20","author":"Barkhof","year":"2014","journal-title":"Mult. Scler. J."},{"issue":"7","key":"10.1016\/j.jns.2025.123577_bb0140","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","volume":"28","author":"van Lierop","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2025.123577_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.875456","article-title":"Calculating and comparing the annualized relapse rate and estimating the confidence interval in relapsing neurological diseases","volume":"13","author":"Akaishi","year":"2022","journal-title":"Front. Neurol."},{"issue":"22","key":"10.1016\/j.jns.2025.123577_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213759","article-title":"Acute effects of ocrelizumab infusion in multiple sclerosis patients","volume":"23","author":"Akg\u00fcn","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2025.123577_bb0155","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jns.2025.123577_bb0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clineuro.2016.07.001","article-title":"Effectiveness and safety of natalizumab in real-world clinical practice: review of observational studies","volume":"149","author":"van Pesch","year":"2016","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jns.2025.123577_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102543","article-title":"Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: a longitudinal, retrospective study","volume":"46","author":"Horakova","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.123577_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106009","article-title":"Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol","volume":"95","author":"Ontaneda","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.jns.2025.123577_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104216","article-title":"Benefits of early treatment with natalizumab: a real-world study","volume":"68","author":"Ontaneda","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.jns.2025.123577_bb0180","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5603\/PJNNS.a2023.0050","article-title":"Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-Centre, retrospective, cohort study during the COVID-19 pandemic","volume":"57","author":"St\u0119pie\u0144","year":"2023","journal-title":"Neurol. Neurochir. Pol."},{"issue":"3","key":"10.1016\/j.jns.2025.123577_bb0185","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.jns.2025.123577_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102945","article-title":"A real-world single-Centre analysis of alemtuzumab and cladribine for multiple sclerosis","volume":"52","author":"Bose","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.jns.2025.123577_bb0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2020-000108","article-title":"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study","volume":"3","author":"Smoot","year":"2021","journal-title":"BMJ Neurol. Open"},{"issue":"12","key":"10.1016\/j.jns.2025.123577_bb0200","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.jns.2025.123577_bb0205","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/ene.15171","article-title":"Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: a primary analysis from the phase 3b CASTING single-arm, open-label trial","volume":"29","author":"Vermersch","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"13","key":"10.1016\/j.jns.2025.123577_bb0210","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123577_bb0215","series-title":"Sex and Gender Differences in Neurological Disease","first-page":"129","article-title":"Chapter Five - Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD)","author":"Diem","year":"2022"},{"issue":"6","key":"10.1016\/j.jns.2025.123577_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0122686","article-title":"Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS","volume":"10","author":"Ribbons","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jns.2025.123577_bb0225","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/135245859900500307","article-title":"Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity","volume":"5","author":"Rae-Grant","year":"1999","journal-title":"Mult. Scler. J."},{"issue":"3","key":"10.1016\/j.jns.2025.123577_bb0230","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jns.2025.123577_bb0235","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-023-11943-4","article-title":"Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension","volume":"271","author":"Kappos","year":"2024","journal-title":"J. Neurol."},{"issue":"16","key":"10.1016\/j.jns.2025.123577_bb0240","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123577_bb0245","first-page":"68","article-title":"Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease","author":"Peters","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.jns.2025.123577_bb0250","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s10072-024-07449-0","article-title":"Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario","volume":"45","author":"Lorefice","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2025.123577_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105570","article-title":"Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: real-world experience of two Swiss multiple sclerosis centers","volume":"86","author":"Diem","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.jns.2025.123577_bb0260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/archneur.1991.00530150067020","article-title":"An assessment of disability rating scales used in multiple sclerosis","volume":"48","author":"Francis","year":"1991","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.123577_bb0265","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","article-title":"Outcome measures in clinical trials for multiple sclerosis","volume":"31","author":"van Munster","year":"2017","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.jns.2025.123577_bb0270","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1177\/1352458516675039","article-title":"Importance of early treatment initiation in the clinical course of multiple sclerosis","volume":"23","author":"Kavaliunas","year":"2017","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.jns.2025.123577_bb0275","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s42466-021-00140-1","article-title":"Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions","volume":"3","author":"Wiendl","year":"2021","journal-title":"Neurol. Res. Pract."},{"issue":"10","key":"10.1016\/j.jns.2025.123577_bb0280","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/brain\/awaa251","article-title":"Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis","volume":"143","author":"Amato","year":"2020","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.jns.2025.123577_bb0285","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25001947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25001947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T09:39:56Z","timestamp":1754473196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25001947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":57,"alternative-id":["S0022510X25001947"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.123577","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.123577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123577"}}